Improved survival and complete response rates in patients with advanced melanoma treated with concurrent ipilimumab and radiotherapy versus ipilimumab alone

References

• Ferri F. Melanoma. In: Ferri's Clinical Adviser. 2nd ed.; 2017:773-5
   Google Scholar
• Gangadhar TC, Fecher LA, Miller CJ, et al. Melanoma. Abeloff's Clin Oncol 2014; 1071-91:e3
   Google Scholar
• Webster RM, Mentzer SE. The malignant melanoma landscape. Nat Rev Drug Discov 2014; 13(7):491-2; PMID:24981356; http://dx.doi.org/10.1038/nrd4326
   PubMed Web of Science ®Google Scholar
• Miller AJ, Mihm MC. Melanoma. N Engl J Med 2006; 355(1):51-65; PMID:16822996; http://dx.doi.org/10.1056/NEJMra052166
   PubMed Web of Science ®Google Scholar
• Sondak VK, Smalley KS, Kudchadkar R, Grippon S, Kirkpatrick P. Ipilimumab. Nat Rev Drug Discov 2011; 10:411-2; PMID:21629286; http://dx.doi.org/10.1038/nrd3463
   PubMed Web of Science ®Google Scholar
• Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363(8):711-23; PMID:20525992; http://dx.doi.org/10.1056/NEJMoa1003466
   PubMed Web of Science ®Google Scholar
• Lipson EJ, Drake CG. Ipilimumab: An anti-CTLA-4 antibody for metastatic melanoma. Clin Cancer Res 2011; 17(22):6958-62; PMID:21900389; http://dx.doi.org/10.1158/1078-0432.CCR-11-1595
   PubMed Web of Science ®Google Scholar
• Callahan MK, Postow MA, Wolchok JD. Immunomodulatory therapy for melanoma: Ipilimumab and beyond. Clin Dermatol 2013; 31(2):191-9; PMID:23438382; http://dx.doi.org/10.1016/j.clindermatol.2012.08.006
   PubMed Web of Science ®Google Scholar
• Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364(26):2517-26; PMID:21639810; http://dx.doi.org/10.1056/NEJMoa1104621
   PubMed Web of Science ®Google Scholar
• Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, Patt D, Chen TT, Berman DM, Wolchok JD. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. J Clin Oncol 2015; 33(17):1889-94; PMID:25667295; http://dx.doi.org/10.1200/JCO.2014.56.2736
   PubMed Web of Science ®Google Scholar
• Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med 2015; 373(1):23-34; PMID:26027431; http://dx.doi.org/10.1056/NEJMoa1504030
   PubMed Web of Science ®Google Scholar
• Chandra RA, Wilhite TJ, Balboni TA, Alexander BM, Spektor A, Ott PA, Ng AK, Hodi FS, Schoenfeld JD. A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab. Oncoimmunology 2015; 4(11):e1046028; PMID:26451318; http://dx.doi.org/10.1080/2162402X.2015.1046028
   PubMed Web of Science ®Google Scholar
• Grimaldi AM, Simeone E, Giannarelli D, Muto P, Falivene S, Borzillo V, Giugliano FM, Sandomenico F, Petrillo A, Curvietto M, et al. Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy. Oncoimmunology 2014; 3:e28780; PMID:25083318; http://dx.doi.org/10.4161/onci.28780
   PubMed Web of Science ®Google Scholar
• Barker CA, Postow MA, Khan SA, Beal K, Parhar PK, Yamada Y, Lee NY, Wolchok JD. Concurrent radiotherapy and ipilimumab immunotherapy for patients with melanoma. Cancer Immunol Res 2013; 1(2):92-8; PMID:24777500; http://dx.doi.org/10.1158/2326-6066.CIR-13-0082
   PubMed Web of Science ®Google Scholar
• Silk AW, Bassetti MF, West BT, Tsien CI, Lao CD. Ipilimumab and radiation therapy for melanoma brain metastases. Cancer Med 2013; 2(6):899-906; PMID:24403263; http://dx.doi.org/10.1002/cam4.140
   PubMed Web of Science ®Google Scholar
• Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol 2013; 31(1):51-72; PMID:23157435; http://dx.doi.org/10.1146/annurev-immunol-032712-100008
   PubMed Web of Science ®Google Scholar
• Golden EB, Apetoh L. Radiotherapy and Immunogenic Cell Death. Semin Radiat Oncol 2015; 25(1):11-7; PMID:25481261; http://dx.doi.org/10.1016/j.semradonc.2014.07.005
   PubMed Web of Science ®Google Scholar
• Hammerich L, Bhardwaj N, Kohrt HE, Brody JD. In situ vaccination for the treatment of cancer. Immunotherapy 2016; 8(3):315-30; PMID:26860335; http://dx.doi.org/10.2217/imt.15.120
   PubMed Web of Science ®Google Scholar
• Pierce RH, Campbell JS, Pai SI, Brody JD, Kohrt HEK. In-situ tumor vaccination: Bringing the fight to the tumor. Hum Vaccines Immunother 2015; 11(8):1901-9; PMID:26055074; http://dx.doi.org/10.1080/21645515.2015.1049779
   PubMed Web of Science ®Google Scholar
• Derer A, Deloch L, Rubner Y, Fietkau R, Frey B, Gaipl US. Radio-immunotherapy-induced immunogenic cancer cells as basis for induction of systemic anti-tumor immune responses - pre-clinical evidence and ongoing clinical applications. Front Immunol 2015; 6:505; PMID:26500646; http://dx.doi.org/10.3389/fimmu.2015.00505
   PubMed Web of Science ®Google Scholar
• Vanpouille-Box C, Pilones KA, Wennerberg E, Formenti SC, Demaria S. In situ vaccination by radiotherapy to improve responses to anti-CTLA-4 treatment. Vaccine 2015; 33(51):7415-22; PMID:26148880; http://dx.doi.org/10.1016/j.vaccine.2015.05.105
   PubMed Web of Science ®Google Scholar
• Shen RN, Hornback NB, Shidnia H, Lu L, Montebello JF, Brahmi Z. A comparison of lung metastases and natural killer cell activity in daily fractions and weekly fractions of radiation therapy on murine B16a melanoma. Radiat Res 1988; 114(2):354-60. http://www.ncbi.nlm.nih.gov/pubmed/3375430; PMID:3375430; http://dx.doi.org/10.2307/3577230
   PubMed Web of Science ®Google Scholar
• Lee Y, Auh SL, Wang Y, Meng Y, Beckett M, Sharma R, Chin R, Tu T, Weichselbaum RR, Fu YX. Therapeutic effects of ablative radiation on local tumor require CD8 + T cells: Changing strategies for cancer treatment. Blood 2009; 114(3):589-95; PMID:19349616; http://dx.doi.org/10.1182/blood-2009-02-206870
   PubMed Web of Science ®Google Scholar
• Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, Mu Z, Rasalan T, Adamow M, Ritter E, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 2012; 366(10):925-31; PMID:22397654; http://dx.doi.org/10.1056/NEJMoa1112824
   PubMed Web of Science ®Google Scholar
• Barker CA, Postow MA. Combinations of radiation therapy and immunotherapy for melanoma: A review of clinical outcomes. Int J Radiat Oncol Biol Phys 2014; 88(5):986-97; PMID:24661650; http://dx.doi.org/10.1016/j.ijrobp.2013.08.035
   PubMed Web of Science ®Google Scholar
• Demaria S, Golden EB, Formenti SC. Role of Local Radiation Therapy in Cancer Immunotherapy. JAMA Oncol 2015; 1:1325-32; PMID:26270858; http://dx.doi.org/10.1001/jamaoncol.2015.2756
   PubMed Web of Science ®Google Scholar
• Hiniker SM, Reddy SA, Maecker HT, Swetter SM, Shura L, Knox SJ. A Prospective Clinical Trial Combining Radiation Therapy With Systemic Immunotherapy in Metastatic Melanoma. Radiat Oncol Biol 2015; 93(3):S95; PMID:27681753; http://dx.doi.org/10.1016/j.ijrobp.2015.07.228
   Google Scholar
• Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, et al. Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer. N Engl J Med 2010; 363(5):411-422; PMID:20818862; http://dx.doi.org/10.1056/NEJMoa1001294
   PubMed Web of Science ®Google Scholar
• Hodi FS, Lee S, McDermott DF, Rao UN, Butterfield LH, Tarhini AA, Leming P, Puzanov I, Shin D, Kirkwood JM. Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial. JAMA 2014; 312(17):1744-53; PMID:25369488; http://dx.doi.org/10.1001/jama.2014.13943
   PubMed Web of Science ®Google Scholar
• Kaufman H, Lutzky J, Clark J, et al. Safety and efficacy of ipilimumab in melanoma patients who received prior immunotherapy on phase III study MDX010-020. ASCO Meet Abstr 2013; 31(15_suppl):9050. http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/9050.
   Google Scholar
• Downey SG, Klapper JA, Smith FO, Yang JC, Sherry RM, Royal RE, Kammula US, Hughes MS, Allen TE, Levy CL, et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res 2007; 13(22 Pt 1):6681-88; PMID:17982122; http://dx.doi.org/10.1158/1078-0432.CCR-07-0187
   PubMed Web of Science ®Google Scholar
• Theurich S, Rothschild SI, Hofmann M, et al. Immunologic Synergy of Local Tumor Treatment in Combination with Systemic Ipilimumab Immunotherapy Prolongs Overall Survival in Patients with Advanced Malignant Melanoma. Cancer Immunol Res. 2016; 2997:1-12; PMID:27466265; http://dx.doi.org/10.1158/2326-6066.CIR-15-0156
   Web of Science ®Google Scholar
• Koller KM, Wang W, Schell TD, Cozza EM, Kokolus KM, Neves RI, Mackley HB, Pameijer C, Leung A, Anderson B, et al. Malignant melanoma—The cradle of anti-neoplastic immunotherapy. Crit Rev Oncol Hematol 2016; 106:25-54
   PubMed Web of Science ®Google Scholar
• Victor CT-S, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, Benci JL, Xu B, Dada H, Odorizzi PM, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 2015; 520(7547):373-7; PMID:25754329; http://dx.doi.org/10.1038/nature14292
   PubMed Web of Science ®Google Scholar